ExAdEx NAM organoids to reduce animal experimentation

ExAdEx NAM organoids to reduce animal experimentation

Organoid models developed by ExAdEx-Innov and collaborators presented at the 3R LÄND CONFERENCE 2024 in Tübingen (Germany)

Latest work from ExAdEx-Innov team on clinically relevant non-animal method (NAM) for human adipose tissue research was selected for a poster presentation at the 3R LÄND Conference 2024 organized by the 3R-Center Tübingen for In vitro Models and Alternatives to Animal Testing at the University of Tübingen and the NMI Natural and Medical Sciences Institute in Reutlingen.

The conference was a great event to meet with renowned academic labs, clinicians, industry representatives and regulatory agencies in the biomedical and pharmaceutical fields, all committed to reduce animal experimentation. 

Organoids and Organ-on-Chip are transforming biomedical and pharmaceutical research and contributing to accurate and human-centered research, reducing reliance on animal testing. ExAdEx real human fat tissue ex vivo maintains the structure and function of native human fat in culture, providing a physiologically human-relevant platform for studying pathological mechanisms of actions and for drug testing.

THE 3R LÄND CONFERENCE 2024

WHERE: Tübinguen (Germany)
WHEN: May 21-23 2024
ABSTRACT TITLE: Donor-derived vascularized organoids modelling inflammation, fibrosis and beiging therapeutical effects of human adipose tissue

The work presented was performed in collaboration with Université Côte d’Azur, the Digestive Surgery Department of Centre Hospitalier Universitaire (CHU) de Nice directed by Professor Antonio Iannelli and received financial support by a Bourse French Tech Emergence by BpiFrance

For more information, please visit website here

Facebook
Twitter
LinkedIn

Latest News

Poster session at IFSCC 2024 with Exsymol

Our Collaboration with Exsymol Monaco at the 34th Congress IFSCC Brazil 2024 We are excited to announce that our scientific research work performed in collaboration

KOL on adipose tissue biology.

Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice). 

Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program). 

Co-inventor of 5 patents

Expert in clinical applications of adipose tissue.

Plastic Reconstructive and Aesthetic Surgeon in Nice.

Member of the Medical Council of Alpes Maritimes region.

Expert for the French National Regulatory Agency ANSM for medical devices.

Certified by French Health Autority HAS (2020-2024).

PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.

Expert in cell therapy and immunology. 

Senior Lecturer (Maitre de conférences).

Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).

Director of « Micoralis » research team at Université Côte d’Azur (Nice).

Founder and CEO of the biotech company Biointerférence (2003-2006).

Co-inventor of 5 patents.

Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.

With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov. 

In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille). 

He is co-inventor of the 2 company’s patent families. 

Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue. 

Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.

With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years. 

He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.

Main areas of expertise: Biotech Startup Business Development; Project management